MM Flashcards

1
Q

Give a general overview of multiple myeloma

A

It is an expansion of the plasma cells - terminally differentiated B cells that secrete Ig and are effector cells of specific humoral immune response
It is the second most common haematopoietic malignancy and affects 4000 people every year in the UK it has a very poor median survival
There is increased incidence with age and the median age of diagnisis is 65-70
It is doubly common in black people and the second most common haem malignancy after lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the aetiology of multiple myeloma?

A

It is not know
Linked to some occupational exposures
There is a 3-4x increased risk in farmers, laxative users, radiologists
Asbestos, petroleum products, pesticides and rubber or wood products are thought to be a risk but really not much is know

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the clinical featues of Multiple myeloma?

A
Bone pain - usually in the back from vertebral fractures
Fatigue
Pneumonia
Paralysising cord compression
CRAB
Hypercalcaemia
Renal Failure
Anaemia
Bone pain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the pre malignant condition for MM?

A

MGUS
Monoclonal gammopathy of undetermined significant
Smouldering myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a plasma cell?

A

Terminally differentiated effector cell of the humoral immune response. It is a very mature fully differenitated b cell which makes antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe b cell development

A

Antigens are recognised by the b cell receptor, this then activates and travels to the lymph node where it becomes somatically hypermutated. They develop similar but different antibodies before further maturing and becoming plasma blasts. The plasma cells then make the antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe how b cell activation can become dysregulated in MM

A

Activation of the b cell requires multiple differentiation proteins, these can become mutated and constitutively switche on which can lead to active cellular processes resulting in the features of myeloma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the key transcription factors that underly the coordinated differentiation process shown?

A
BCL-6
BLIMP1
CIITA 
ID3
PAX 4 
xbp1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Briefly explain how Igs are able to have such heterogeneity

A

VDJ
Random bringing of D segments with J segments and middle DNA removed and deleted
V then added forming VDJ
This is the heavy chain
For the light chain the kappa region is attempted first, if this fails then they try the lamda chain, hence why more kappa than lamda in the blood
Class switching - switching elements in the DNA allow for class switching which can change the class

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the main features of multiple myeloma?

A

Bone lesions - osteolytic bone lesions are visible on x ray
Kidney failure occurs as the light chains which are secreted are filtered by the kidney. The precipitate and clog up the kidneys this occures in the kidney tubules

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe the morphology of a myeloma film

A

Clumped chromatin
Nucleus pushed to one side byt the golgi - this is because the golgi takes a bigger role in manufacturing Igs so is bigger - this is characterised by the light bit in the dark cytoplasm
Nucleus appears dense

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the immunophenotype of myeloma?

A

Positive for: CD38 CD138 CD56/58 monotypic cytoplasmic Ig LC restricted
Negative for: CD19 CD20 and surface Ig

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the cytogenetic analysis of MM?

A
The IgH chain is found on the telomeric region of chromosome 14, the mutations leading to MM therefore can be found to disturb this area
t(4;14)(p16.3;q32): IGH-FGFR3-MMSET1
t(11;14)(q13;q32): IGH-Cyclin D1
t(6;14)(p21;q32): IGH-cyclin D3
t(14;16)(q32;q32): IGH-c-MAF 

Del(13q) adverse prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe what happens with the MMSET gene

A

MMSET interacts with proteins to activate oncogenic signalling pathways, this establishes causal roles for MMSET in driving cancer initiation development and survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Which are the mutations with the worst prognosis?

A
Monosomy 13q (50% of MM)- worst prognosis
t(4;14)(p16.3;q32) - FGFR3-MMSET1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is a mutation seen in light chain myeloma?

A

t(11;14)(q13;q32) this leads to overexpression of cyclin D1

it is associated with a good prognosis

17
Q

In indolent MGUS patients what is the treatment?

A

Watch and wait there is no benefit to starting early in mgus

18
Q

What is the definitive treatment of MM?

A

Autologous stem cell transplant

19
Q

What is the choice of chemotherapy regimen for autologous stem cell transplant?

A

Standard - Melphalan +/- prednisolone

High dose - Cyclophosphamide, thalidomide, dexamethasone

20
Q

In who should a SCT be considered and what are the risks?

A

SCT to be considered in anyone under 55 with a matched sibling
High risk of relapse and high treatmetn related mortality involved

21
Q

What is given in refractory myeloma?

A

Thalidomide is given as there is low renal excretion
TNFalpha and angiogenesis is suppressed
Bortezomid is also used, it is a proteasome inhibitor which leads to reduced activity of NfKB